Biotech in boom cycle

Baker, John
April 2007
ICIS Chemical Business;4/23/2007, Vol. 2 Issue 63, p36
Trade Publication
The article reports on the growth of Europe's biotechnology industry as of April 23, 2007. Biotechnology revenues grew by 13% to €13.3bn ($18.1bn) in 2006, sustaining the momentum the sector began to display in 2005 after two years of contraction. Globally, revenues from publicly traded biotechnology companies rose by 14% in 2006 to reach $73.4bn (€54.1bn). Financing increased by 45% to €4.7bn, with venture capital financing at an all-time high of €1.5bn.


Related Articles

  • No magic potion. Dietderich, Andrew; Bailey, Laura // Crain's Detroit Business;6/24/2002, Vol. 18 Issue 25, p3 

    Focuses on the initiatives of life-science companies to confront with the slow economy in Michigan. Extent of competition for funding in the industry; Assessment on the survival of the companies; Advantages of small and large companies in the industry.

  • Cash-strapped firms face stormy time. Mitchell, Peter // Nature Biotechnology;Jan2002, Vol. 20 Issue 1, p5 

    Reports that a significant number of European biotechnology companies are in danger of closing within a year unless they can reinvent their business plans and raise new cash, according to a consensus of industry observers. Reasons why investors abandon early-stage companies; European companies...

  • Financings Roundup.  // BioWorld Today;9/29/2010, Vol. 21 Issue 188, p8 

    This section offers news briefs on financing activities in the biotechnology industry, including the Horizon Discovery Ltd. Seriec C financing, Titan Pharmaceuticals Inc.'s amended loan and security agreement with Oxford Finance Corp., and Tigris Pharmaceuticals Inc.'s private placement of...

  • FINANCINGS ROUNDUP.  // BioWorld Today;2/22/2010, Vol. 21 Issue 34, p7 

    This section offers news briefs on financing for the biotechnology industry, including a grant from the BuiCrossroads Indiana Seed Fund to Bioscience Vaccines Inc., the exercise of the overallotment option by underwriters of its public offering of stock and warrants and an at-the-market program...

  • FINANCINGS ROUNDUP.  // BioWorld Today;2/26/2010, Vol. 21 Issue 38, p7 

    This section offers finance-related news briefs within the biotechnology industry including the decision of Palatin Technologies Inc. to sell common stock in a registered direct offering and the increase in Trius Therapeutics Inc.'s proposed initial public offering to fund Phase III trials of an...

  • Coming Monday in BioWorld Insight.  // BioWorld Today;3/15/2013, Vol. 24 Issue 50, p7 

    The section offers news briefs related to the biotechnology industry as of March 15, 2013 including one on the multiple strategies used by large pharmaceutical companies to build early stage pipelines, one on an anti-age old debate over Sirtuin research, and one on biotech companies targeting to...

  • Bubble, Bubble, Toil and Trouble. Boorstin, Julia // Fortune;6/11/2001, Vol. 143 Issue 12, p48 

    Discusses the financial status of biotechnology companies in the United States. Drop in the share prices of the companies; How many continue to attract venture capital; Opinion that many have enough money to survive the economic downturn; Suggestion that companies that can not survive will be...

  • Financings Roundup.  // BioWorld Today;5/22/2012, p8 

    This section offers news briefs on financing for biotechnology companies, including the second closing of the Series B round of financing of Prosonix Ltd. of Great Britain which raised an additional 5.7 million British pounds.

  • Of Mammals and Men. Roy, Ayon // Siliconindia;Aug2002, Vol. 6 Issue 8, p26 

    Focuses on the finance for the Tranzyme Inc., a biotechnology company in Alabama. Attraction of the collaborators on the technological platforms of the company; List of partners of the company; Features of TranzEmbryo product.


Other Topics